Differences in Postprandial Glucose Changes
An Intervention Comparing Changes in the Plasma Glucose Profile Over a Three-hour Timespan in Persons With T2DM Following Caribbean Shake vs Glucerna Intake: A Double Blinded, Cross-over Design
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A diagnosis of T2DM for any length of time,
- last HbA1C (within the last 6 months) of < / = 8%
Exclusion Criteria:
1. On insulin for any length of time
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Shake 1 then Shake 2
Participants will consume 1 bottle of shake 1 and take their normal morning medications.
After this 3ml blood samples will be taken via the cannula at 30mins, 60mins and 120 mins post meal.
During the waiting period between phlebotomy, a sensory analysis questionnaire which asks participants to rate the taste, appearance, texture and smell of the product.
After a 1-week washout period, the entire protocol will be repeated using Shake 2.
|
Oral administration of Caribbean low-calorie meal-replacement shake then commercial low-calorie meal-replacement shake
|
|
Experimental: Shake 2 then Shake 1
Participants will consume 1 bottle of Shake 2 and take their normal morning medications.
After this 3ml blood samples will be taken via the cannula at 30mins, 60mins and 120 mins post meal.
During the waiting period between phlebotomy, a sensory analysis questionnaire which asks participants to rate the taste, appearance, texture and smell of the product.
After a 1-week washout period, the entire protocol will be repeated using Shake 1.
|
Oral administration of commercial low-calorie meal-replacement shake then Caribbean low-calorie meal-replacement shake
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in plasma glucose concentration post oral intake of shake
Time Frame: 30 minutes, 60 minutes and 120 minutes post oral intake of shake
|
30 minutes, 60 minutes and 120 minutes post oral intake of shake
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensory analysis of taste, texture, smell and appearance of shakes
Time Frame: within 1hour post oral intake of shake
|
measured on a 5-point hedonic scale
|
within 1hour post oral intake of shake
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SHIFT
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.